Leptomeningeal metastasis

Seminars in Neurology

Volumn 30, Issue 3, 2010, Pages 236-244

  Chamberlain, Marc C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

intra CSF chemotherapy; Leptomeningeal metastases

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; CD20 ANTIBODY; CORTICOSTEROID; CYTARABINE; DIAZIQUONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; GEMCITABINE; INTERLEUKIN 2; MAFOSFAMIDE; METHOTREXATE; MONOCLONAL ANTIBODY I 131; PROTEIN ANTIBODY; PSYCHOSTIMULANT AGENT; RADIOISOTOPE; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; TRASTUZUMAB;

ASEPTIC MENINGITIS; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BRAIN; BRAIN CANCER; BRAIN HEMORRHAGE; BRAIN INFECTION; BREAST; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CEREBROSPINAL FLUID CULTURE; CEREBROSPINAL FLUID FLOW; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; FEVER; HEADACHE; HUMAN; HYDROCEPHALUS; LEPTOMENINGEAL METASTASIS; LEPTOMENINX; LEUKOENCEPHALOPATHY; LYMPHOMA; MOTOR DYSFUNCTION; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NEURORADIOLOGY; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PALLIATIVE THERAPY; PANCYTOPENIA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTECTION; REVIEW; SENSORY DYSFUNCTION; SEPTICEMIA; SOLID TUMOR; SOMNOLENCE; SPINE; TREATMENT INDICATION; ARTICLE; MENINGIOMA; METASTASIS; PATHOPHYSIOLOGY;

HUMANS; MENINGEAL NEOPLASMS;

EID: 77954155076     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0030-1255220     Document Type: Review

References (80)

1. Jaeckle K A. Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol 2006 33 (3) 312-323
2. Pace A, Fabi A. Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol 2006 60 (3) 194-200
3. Kaplan J G., DeSouza T G., Farkash A et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990 9 (3) 225-229
4. Siegal T, Lossos A, Pfeffer M R. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994 44 (8) 1463-1469
5. Blaney S M., Poplack D G. Neoplastic meningitis: diagnosis and treatment considerations. Med Oncol 2000 17 (3) 151-162
6. Glass J P., Melamed M, Chernik N L., Posner J B. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979 29 (10) 1369-1375
7. Wasserstrom W R., Glass J P., Posner J B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982 49 (4) 759-772
8. Rosen S T., Aisner J, Makuch R W. et al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore) 1982 61 (1) 45-53
9. Amer M H., Al-Sarraf M, Baker L H., Vaitkevicius V K. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978 42 (2) 660-668
10. van Oostenbrugge R J., Twijnstra A. Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology 1999 53 (2) 382-385
11. Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996 53 (7) 626-632
12. Sorensen S C., Eagan R T., Scott M. Meningeal carcinomatosis in patients with primary breast or lung cancer. Mayo Clin Proc 1984 59 (2) 91-94
13. Gonzalez-Vitale J C., Garcia-Bunuel R. Meningeal carcinomatosis. Cancer 1976 37 (6) 2906-2911
14. Gleissner B, Chamberlain M C. Neoplastic meningitis. Lancet Neurol 2006 5 (5) 443-452
15. Boyle R, Thomas M, Adams J H. Diffuse involvement of the leptomeninges by tumoura clinical and pathological study of 63 cases. Postgrad Med J 1980 56 (653) 149-158
16. Wolfgang G, Marcus D, Ulrike S. Leptomeningeal carcinomatosis; clinical syndrome in different primaries. J Neurooncol 1998 38 103-110
17. Klmel H W. Cytology of neoplastic meningosis. J Neurooncol 1998 38 (2-3) 121-125
18. Murray J J., Greco F A., Wolff S N., Hainsworth J D. Neoplastic meningitis. Marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med 1983 75 (2) 289-294
19. Rogers L R., Duchesneau P M., Nunez C et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology 1992 42 (6) 1239-1241
20. Chamberlain M C., Kormanik P A., Glantz M J. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro-oncol 2001 3 (1) 42-45
21. Glantz M J., Cole B F., Glantz L K. et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998 82 (4) 733-739
22. Groves M D., Hess K R., Puduvalli V K. et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 2009 94 (2) 229-234
23. Chamberlain M C. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology 1998 50 (4) 1173-1175
24. Hovestadt A, Henzen-Logmans S C., Vecht C J. Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis. Br J Cancer 1990 62 (4) 653-654
25. van Oostenbrugge R J., Hopman A H., Ramaekers F C., Twijnstra A. In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis. J Neurooncol 1998 38 (2-3) 127-133
26. Quijano S, Lpez A, Manuel Sancho J et al, Spanish Group for the Study of CNS Disease in NHL. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol 2009 27 (9) 1462-1469
27. Bromberg J EC, Breems D A., Kraan J et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 2007 68 (20) 1674-1679
28. Hegde U, Filie A, Little R F. et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005 105 (2) 496-502
29. Cheng T M., O'Neill B P., Scheithauer B W., Piepgras D G. Chronic meningitis: the role of meningeal or cortical biopsy. Neurosurgery 1994 34 (4) 590-595 discussion 596
30. Chamberlain M C., Sandy A D., Press G A. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990 40 (3 Pt 1) 435-438
31. Schumacher M, Orszagh M. Imaging techniques in neoplastic meningiosis. J Neurooncol 1998 38 (2-3) 111-120
32. Chamberlain M C. Comparative spine imaging in leptomeningeal metastases. J Neurooncol 1995 23 (3) 233-238
33. Freilich R J., Krol G, DeAngelis L M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995 38 (1) 51-57
34. Mittl R L. Jr, Yousem D M. Frequency of unexplained meningeal enhancement in the brain after lumbar puncture. AJNR Am J Neuroradiol 1994 15 (4) 633-638
35. Chamberlain M C. Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol 1998 38 (2-3) 135-140
36. Glantz M J., Hall W A., Cole B F. et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995 75 (12) 2919-2931
37. Grossman S A., Trump C L., Chen D C., Thompson G, Camargo E E. Cerebrospinal flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med 1982 73 641-647
38. Chamberlain M C., Kormanik P A. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 1996 46 (6) 1674-1677
39. Mason W P., Yeh S D., DeAngelis L M. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1998 50 (2) 438-444
40. Chamberlain M C., Corey-Bloom J. Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology 1991 41 (11) 1765-1769
41. Chamberlain M C., Kormanik P, Jaeckle K A., Glantz M. 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1999 52 (1) 216-217
42. Chamberlain M C., Kormanik P A. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol 1997 54 (11) 1364-1368
43. Chamberlain M C. Neoplastic meningitis-related encephalopathy: prognostic significance. Neurology 2004 63 2159-2161
44. Chamberlain M C. Neoplastic meningitis: deciding who to treat. Expert Rev Neurother 2004 4 89-96
45. Brem S S., Bierman P J., Black P et al. Central nervous system cancers. J Natl Compr Canc Netw 2008 6 (5) 456-504
46. Shapiro W R., Young D F., Mehta B M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975 293 (4) 161-166
47. Grossman S A., Finkelstein D M., Ruckdeschel J C., Trump D L., Moynihan T, Ettinger D S., Eastern Cooperative Oncology Group. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 1993 11 (3) 561-569
48. Glantz M J., Jaeckle K A., Chamberlain M C. et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999 5 (11) 3394-3402
49. Glantz M J., LaFollette S, Jaeckle K A. et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999 17 (10) 3110-3116
50. Shapiro W R., Schmid M, Glantz M, Miller J J. A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol 2006 24 (Suppl) 1528 (Abstract)
51. Chamberlain M C. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer 2002 94 (10) 2675-2680
52. Chamberlain M C., Wei-Tsao D D., Groshen S. Phase 2 trial of intra-CSF etoposide in the treatment of neoplastic meningitis. Cancer 2006 106 (9) 2021-2027
53. Groves M D., Glantz M J., Chamberlain M C. et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-oncol 2008 10 (2) 208-215
54. Chamberlain M C., Johnston S K., Van Horn A, Glantz M J. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 2009 91 (3) 271-277
55. Rubenstein J L., Fridlyand J, Abrey L et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007 25 (11) 1350-1356
56. Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 2008 19 (11) 1978-1980
57. Allison D, Glantz M. Intra-CSF Trastuzumab in patients with neoplastic meningitis from breast cancer or primary brain tumors. Neurology 2009 72 (11, Suppl 3) A30
58. Chamberlain M C. Risk of neoplastic meningitis following surgical resection of cerebellar metastases. J Neurooncol 2008 89 (1) 105-107
59. Berweiler U, Krone A, Tonn J C. Reservoir systems for intraventricular chemotherapy. J Neurooncol 1998 38 (2-3) 141-143
60. Sandberg D I., Bilsky M H., Souweidane M M., Bzdil J, Gutin P H. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 2000 47 (1) 49-54 discussion 54-55
61. Glantz M J., Van Horn A, Fisher R, Chamberlain M C. Route of intra-CSF chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer 2010 116 (8) 1947-1952
62. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol 1998 38 (2-3) 151-157
63. Boogerd W, van den Bent M J., Koehler P J. et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004 40 (18) 2726-2733
64. Hitchins R N., Bell D R., Woods R L., Levi J A. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987 5 (10) 1655-1662
65. Chamberlain M C., Kormanik P A., Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997 87 (5) 694-699
66. Siegal T, Pfeffer M R., Steiner I. Antibiotic therapy for infected Ommaya reservoir systems. Neurosurgery 1988 22 (1 Pt 1) 97-100
67. Kerr J Z., Berg S, Blaney S M. Intrathecal chemotherapy. Crit Rev Oncol Hematol 2001 37 (3) 227-236
68. Stapleton S, Blaney S M. New agents for intrathecal administration. Cancer Invest 2006 24 (5) 528-534
69. Glantz M J., Cole B F., Recht L et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998 16 (4) 1561-1567
70. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 1998 82 (9) 1756-1763
71. Sampson J H., Archer G E., Villavicencio A T. et al. Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res 1999 5 (5) 1183-1188
72. Bernardi R J., Bomgaars L, Fox E et al. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol 2008 62 (2) 355-361
73. Herrlinger U, Weller M, Schabet M. New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol 1998 38 (2-3) 233-239
74. Coakham H B., Kemshead J T. Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients. J Neurooncol 1998 38 (2-3) 225-232
75. Chamberlain M C., Kormanik P R. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 1997 35 (1) 55-64
76. Chamberlain M C., Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 1998 55 (4) 506-512
77. Chamberlain M C., Johnston S K., Glantz M J. Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol 2009 66 (1) 74-78
78. Chamberlain M C., Johnston S K. Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology. Cancer 2009 115 (9) 1941-1946
79. Garcia-Marco J A., Panizo C, Garcia E S. et al. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 2009 115 (9) 1892-1898
80. Jaeckle K A., Batchelor T, O'Day S J. et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 2002 57 (3) 231-239